About Mast Therapeutics
We are a publicly traded biopharmaceutical company headquartered in San Diego, California.
We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.
To learn more about our company, please see our Letter from the CEO.Follow Us! >> 
News
Click here to view our latest press releases, SEC filings, and information about company events, media, and analyst coverage.
read more
Technology
Click here to learn more about our lead product candidate, MST-188, as well as our other technologies.
read more
Clinical Trials
We have initiated a Phase 3 clinical study of MST-188 for the treatment of sickle cell disease. See our Clinical Trials page for more info.
read more